Bhutan vs Eswatini: Average cost of drugs for extensively drug-resistant tuberculosis
Bhutan
2,259 constant 2022 US$
in 2024
Eswatini
2,726 constant 2022 US$
in 2024
Bhutan rank
23rd
Eswatini rank
22nd
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Bhutan
- Eswatini
How they compare
Eswatini currently reports 2,726 constant 2022 US$ against 2,259 constant 2022 US$ in Bhutan, a difference of 467 constant 2022 US$.
That makes Eswatini's figure about 1.2 times Bhutan's.
The two have swapped places 2 times across 6 shared years of data; in 2019 it was Eswatini ahead.
Bhutan ranks 23rd and Eswatini ranks 22nd of 56 countries.
Eswatini has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Bhutan | Eswatini | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,951 constant 2022 US$ | 14,249 constant 2022 US$ | 11,298 constant 2022 US$ | Eswatini |
| 2020s | 2,259 constant 2022 US$ | 9,624 constant 2022 US$ | 7,365 constant 2022 US$ | Eswatini |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Bhutan or Eswatini?
- Eswatini, at 2,726 constant 2022 US$ against 2,259 constant 2022 US$ in Bhutan as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Bhutan and Eswatini?
- 467 constant 2022 US$, with Eswatini ahead.
- How many years of comparable data are there for Bhutan and Eswatini?
- 6 years are reported by both, from 2019 to 2024.
- How do Bhutan and Eswatini rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Bhutan ranks 23rd and Eswatini ranks 22nd of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.